Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Daratumumab in RRMM
NCT04361851Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jun 2021
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of pembrolizumab in multiple myeloma (MM), sponsored by Wake Forest University Health Sciences. Primary endpoint: 8-Month Progression-Free Survival. Planned start Jun 2021; status: withdrawn.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04361851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04361851.